Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 8,000 shares at $14.58 ($117K) on 2021-12-27, disclosed to the SEC on 2021-12-29.
Open-market sale of $117k SPRO by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |